Meeting
2013 ASCO Annual Meeting
PROSELICA study update: Comparison of two doses of cabazitaxel (Cbz) plus prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel (D)-containing regimen.
Authors
Mario A. Eisenberger
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University; James Buchanan Brady Urological Institute, Baltimore, MD
Mario A. Eisenberger , Anne-Claire Hardy-Bessard , Daniel Ford , Loic Mourey , Phillip Parente , Paul N. Mainwaring , Siobhan Ng , Boris Alekseev , Vsevolod Matveev , Joan Carles , Jeremy Shapiro , Igor Latorzeff , Istvan Bodrogi , Choung-Soo Kim , Albert Font , Roanne Segal , Hendrik Pieter Van Den Berg , Wenping (Wendy) Zhang , Mustapha Chadjaa , Johann Sebastian De Bono
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer
Sub Track
Prostate Cancer
Clinical Trial Registration Number
NCT01308580
Citation
J Clin Oncol 31, 2013 (suppl; abstr TPS5099^)
DOI
10.1200/jco.2013.31.15_suppl.tps5099
Abstract #
TPS5099^
Poster Bd #
43B
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Comparison of two doses of cabazitaxel plus prednisone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel (D)-containing regimen.
First Author: Mario A. Eisenberger
Poster
2015 Genitourinary Cancers Symposium
Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E)
First Author: Ethan M. Basch
Poster
2012 ASCO Annual Meeting
First-line use of cabazitaxel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm study in comparison with docetaxel.
First Author: Stephane Oudard
Poster
2014 Genitourinary Cancers Symposium
Regional analysis of a cohort compassionate-use program (CUP) and early access program (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz + P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D).
First Author: Zafar Malik